Covaxin to cost Rs 1,200 per dose for private hospitals, Rs 600 for states

Bharat Biotech noted that the manufacturing process was expensive due to low process yields, and that it was important to recover costs to invest in future R&D

Covaxin
Covaxin (Photo: Bloomberg)
Sohini Das Mumbai
1 min read Last Updated : Apr 24 2021 | 10:54 PM IST
Bharat Biotech's Covaxin will be available to state governments at Rs 600 a dose and private hospitals at Rs 1,200 a dose, the Hyderabad-based company said late on Saturday.
 
Serum Institute earlier said that its vaccine would cost Rs 400 per dose for state governments and Rs 600 per dose for private hospitals.
 
Bharat Biotech said that the vaccine not only had an excellent safety profile but it was formulated with adjuvants to improve immune response. Further, once opened, the vial could be kept at 2-8 degrees for 28 days, thus reducing wastage, it claimed.
 
The Phase-III clinical studies have shown that the vaccine has 78 per cent efficacy against Covid 19, and 100 per cent against a severe form of the disease. The company also noted that the manufacturing process was expensive due to low process yields, and that it was important to recover costs to invest in future R&D.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBharat BiotechHealth crisis

Next Story